Three ANZ startups raise $18.75M: cancer tech, AI infra, concrete recycling
Three Australian startups closed funding this week, totalling $18.75 million across oncology, infrastructure software, and construction materials.
Skopos Bio: $12M seed
Melbourne precision oncology startup Skopos Bio raised $12 million seed from Andrew Forrest's Tenmile, John Wylie's Tin Alley Ventures, and Reed Jobs' Yosemite.
The company spun out of Peter MacCallum Cancer Centre in 2024. Founders: Professor Michael Hofman, Associate Professor Mohammad Haskali, Associate Professor Luc Furic.
Product: Radiopharmaceuticals that target cancer cells previously unreachable by conventional drugs. The tech builds on Hofman's earlier prostate cancer theranostic work, now expanding to broader cancer types.
Commercial reality: Early stage, pre-revenue. The raise signals investor confidence in regulated medical tech, but go-to-market timeline is years away. No sales team disclosed.
Trendspek and R2Crete
The other two raises in the roundup: Trendspek (AI tools for infrastructure assessment) and R2Crete (waste concrete processing). Funding amounts not disclosed beyond the $18.75M total.
Neither company has published sales team details, revenue metrics, or customer counts. Standard for early infrastructure and materials tech, where pilot programs and engineering partnerships precede traditional B2B sales motion.
What it means
Australian startup funding stayed active through late September 2026, with investors backing AI-enabled enterprise plays and regulated-market businesses. The Skopos round continues the pattern of offshore capital (Yosemite is US-based) backing ANZ health and deep tech.
For sales professionals: These raises mean eventual hiring, but timeline is unclear. Skoops Bio will need commercial partnerships and regulatory approval before building an ANZ or US sales team. Infrastructure and materials startups typically hire technical account managers before traditional AEs.
No comp details, no headcount projections, no territory plans disclosed. Par for the course at seed stage, but worth tracking as these companies scale.